An informative open access article was published on the current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. As one can tell from the article, the number of clincial trials for CAR-T multiple myeloma therapies is still rather low. While other clincial trials target BCMA as target, CARAMBA targets the SLAMF7 antigen. If you are interested in the full article, please visit Nature’s Gene Therapy Journal.

Share This